Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Biosimilar Litigation Trends: Settlements, Declaratory Judgment Rejections, Congressional Intervention

Aug 12 2018

• By Brenda Sandburg

Close up golden chess pieces with blurry judge gravel and law book background.

Related Content

Adello’s Filgrastim Biosimilar Faces Infringement Lawsuit And Potential Regulatory Delay

May 29 2018

Humira's 'Unique' Number Of Patents Makes Biosimilar Entry Risky, Pfizer Says

Apr 11 2018

Biosimilar Litigation: Celltrion, Pfizer Claim Victory On Janssen’s Remaining Infringement Claim

Aug 01 2018

Avoiding ‘Groundhog Day’: US FDA’s Biosimilar Action Plan Applies Lessons From Generic Competition

Jul 23 2018

Pay-For-Delay Settlements Decline In Wake Of Supreme Court Ruling

Nov 02 2017

Biosimilar Legal Landscape: Lessons From 2017

Jan 03 2018

Biosimilar Suits: Another Court To Rule On Declaratory Judgement Timing

Jan 29 2018

Related Companies

Genentech, Inc.

Celltrion, Inc.

AbbVie Inc.

Amgen, Inc.

Samsung Bioepis Co., Ltd.

Viatris Inc.

Boehringer Ingelheim GmbH

Pfizer Inc.

Hospira, Inc.

Apotex Inc.

Novartis AG

Coherus Oncology, Inc.

Teva Pharmaceutical Industries Ltd.

Allergan plc

Additional Topics

United States Biosimilars Intellectual Property Legal Issues Policy BioPharmaceutical

More from Biosimilars

More from Biosimilars & Generics

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window